Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Off-pump Coronary Artery Bypass Graft

Completed

Brief Summary: High mobility group 1 (HMGB1) protein is both a nuclear factor and a secreted protein, and has recently been identified as a cytokine mediator of systemic inflammation. HMGB1 is released by inflammatory cells actively, or increased during cell death passively and mediates inflammatory response. It has been reported to have association with the prognosis after acute coronary syndrome, ischemia-reperfusion injury of myocardium, atherosclerosis and heart failure. This study aimed to investigate the relationship of serum levels of HMGB1 and post operative prognosis of patients who had undergone off-pump coronary artery bypass graft.

Recruitment & Eligibility

Inclusion Criteria

Exclusion Criteria

Age < 20
Patients undergoing off-pump coronary artery bypass graft with other simultaneous surgery
Patients participating other study

Primary Outcome Measures

Name	Time	Method
Maximum value of HMGB1	Change from induction of anesthesia to 2hrs after transfer to intensive care unit	Measure the maximum value of HMGB1 in all patients and calculate median value. And device into upper median value group and under median value group and compare frequency of composite morbidity/mortality rate between two groups. composite morbidity/mortality is as follows: 1. Stroke 2. Renal failure 3. Prolonged ventilation more than 24 hours 4. Deep sternal wound infection 5. Reoperation for any reason 6. Mortality during the hospitalization for surgery, even if over 30 days

Secondary Outcome Measures

Name	Time	Method

Locations (1): Department of Anesthesiology & Pain Medicine, Yonsei university college of medicine
🇰🇷
Seoul, Korea, Republic of

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial